NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2010
Business Overview: NAI is a leading formulator, manufacturer, and marketer of nutritional supplements. Its primary business is private label contract manufacturing for companies marketing vitamins, minerals, and herbs. It also markets its own branded products under the "Pathway to Healing" line. The company operates manufacturing facilities in San Marcos and Vista, California, and Manno, Switzerland.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total net sales decreased 11% to $65.6 million. Private label contract manufacturing sales dropped 11% due to lower volumes from top customers (NSA International and Mannatech) and the loss of a smaller customer. Branded product sales declined 18% due to the softening of the "Pathway to Healing" line following the discontinuance of Dr. Cherry's television program.
• Profitability Improvement: Despite lower sales, the company returned to profitability with $4.1 million in net income compared to a $4.1 million loss in 2009. This turnaround was driven by a 3.9 percentage point increase in gross margin (to 16.6%) and a $1.4 million reduction in selling, general, and administrative expenses due to cost reduction programs implemented in 2009.
• Discontinued Operations: The legacy Real Health Laboratories (RHL) business was sold in July 2009. In 2010, the company recorded a $157,000 income from discontinued operations, compared to a $3.9 million loss in 2009 which included a $1.8 million impairment charge.
• Debt Elimination: The company paid off all long-term debt during fiscal 2010, resulting in zero consolidated debt as of June 30, 2010.

Guidance, Outlook, and Risks

• Outlook: Management anticipates generating positive net income in the first quarter of fiscal 2011. The company plans to focus on leveraging certified facilities, growing the "Pathway to Healing" line, commercializing its patent estate (specifically beta-alanine/CarnoSyn), and improving operational efficiencies.
• Customer Concentration Risk: Revenue concentration remains a significant risk. The two largest customers, NSA International (52% of sales) and Mannatech (30% of sales), accounted for 82% of total net sales from continuing operations in 2010.
• Key Risks:
  • Loss of major customers or changes in their order timing.
  • Dependence on the "Pathway to Healing" brand and the absence of Dr. Cherry's TV program for customer acquisition.
  • Regulatory compliance with FDA Good Manufacturing Practices (GMP) and international regulations.
  • Supply chain disruptions or raw material cost increases.
• Unusual Items: The 2010 income tax benefit included a $3.2 million federal tax benefit and $0.5 million state tax benefit resulting from the write-off of the tax basis in RHL's stock, deemed worthless in Q3 2010.

Investor Verification Checklist

• Customer Dependency: Verify the stability of relationships with NSA International and Mannatech, which collectively represent over 80% of revenue.
• Branded Product Growth: Assess the effectiveness of new marketing initiatives for the "Pathway to Healing" line in the absence of Dr. Cherry's television exposure.
• Patent Revenue: Monitor royalty income from the beta-alanine sublicense agreement with Compound Solutions, Inc., which contributed to offsetting sales declines.
• Cost Structure: Confirm that the cost savings from the 2009 restructuring programs are sustainable and not one-time benefits.
• Liquidity: Review the utilization of the $7.5 million credit line and the company's ability to fund capital expenditures without additional debt.